Trials / Terminated
TerminatedNCT02662036
Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction
A Prospective Trial to Assess Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy of analgesia provided by liposomal bupivacaine (Exparel) when compared to bupivacaine HCL as a transverse abdominis plane (TAP) block in terms of discharge milestones, opioid use, costs, and patient-reported satisfaction at 12, 24, and 72 hours. The investigators propose that Exparel will lower opioid use, length of stay, and overall cost of abdominally-based autologous breast reconstruction, and will lead to greater patient satisfaction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bupivicaine HCL | |
| DRUG | Liposomal bupivacaine |
Timeline
- Start date
- 2016-02-29
- Primary completion
- 2018-02-26
- Completion
- 2018-03-08
- First posted
- 2016-01-25
- Last updated
- 2019-02-18
- Results posted
- 2019-02-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02662036. Inclusion in this directory is not an endorsement.